Trial Profile
A Randomised Double Blind Phase II Trial to Evaluate the Efficacy of Two Doses of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2020
Price :
$35
*
At a glance
- Drugs Fostamatinib (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors AstraZeneca; Rigel Pharmaceuticals
- 21 Jun 2020 Results of two patients from this trial who continued to benefit from fostamatinib treatment for over 6 years presented at the 25th Congress of the European Haematology Association.
- 31 May 2020 Results of two patients from this trial who continued to benefit from fostamatinib treatment for over 6 years presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 17 Dec 2015 Results published in the European Journal of Cancer